[go: up one dir, main page]

WO2000071708A3 - UTILISATION DE EF-Ts DANS LE CADRE DES HYPERPLASIES DES CELLULES MUSCULAIRES LISSES (CML) - Google Patents

UTILISATION DE EF-Ts DANS LE CADRE DES HYPERPLASIES DES CELLULES MUSCULAIRES LISSES (CML) Download PDF

Info

Publication number
WO2000071708A3
WO2000071708A3 PCT/FR2000/001369 FR0001369W WO0071708A3 WO 2000071708 A3 WO2000071708 A3 WO 2000071708A3 FR 0001369 W FR0001369 W FR 0001369W WO 0071708 A3 WO0071708 A3 WO 0071708A3
Authority
WO
WIPO (PCT)
Prior art keywords
smooth muscle
muscle cell
cell hyperplasia
treating
treating smooth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FR2000/001369
Other languages
English (en)
Other versions
WO2000071708A2 (fr
Inventor
John Mcgregor
Kazem Zibara
Marie-Claude Bourdillon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Publication of WO2000071708A2 publication Critical patent/WO2000071708A2/fr
Publication of WO2000071708A3 publication Critical patent/WO2000071708A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne l'utilisation du gène codant pour EF-Ts de mammifères dans le cadre du traitement et du diagnostique de maladies impliquant les hyperplasies des cellules musculaires lisses (CML), la dé-différenciation des CML et/ou la transformation cellulaire ou cancérogenèse des CML. L'invention porte également sur l'utilisation d'un composé capable d'inhiber l'expression ou l'activité de EF-Ts, notamment d'un oligonucléotide antisens ou d'un anticorps pour le traitement des maladies cardio-vasculaires et du cancer.
PCT/FR2000/001369 1999-05-21 2000-05-19 UTILISATION DE EF-Ts DANS LE CADRE DES HYPERPLASIES DES CELLULES MUSCULAIRES LISSES (CML) Ceased WO2000071708A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9906530A FR2793798A1 (fr) 1999-05-21 1999-05-21 OLIGONUCLEOTIDES ANTISENS DE EF-Ts
FR99/06530 1999-05-21

Publications (2)

Publication Number Publication Date
WO2000071708A2 WO2000071708A2 (fr) 2000-11-30
WO2000071708A3 true WO2000071708A3 (fr) 2001-03-01

Family

ID=9545916

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2000/001369 Ceased WO2000071708A2 (fr) 1999-05-21 2000-05-19 UTILISATION DE EF-Ts DANS LE CADRE DES HYPERPLASIES DES CELLULES MUSCULAIRES LISSES (CML)

Country Status (2)

Country Link
FR (1) FR2793798A1 (fr)
WO (1) WO2000071708A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003104488A1 (fr) * 2002-06-07 2003-12-18 Cancer Care Ontario Utilisation de eef1a2 dans le pronostic, le diagnostic et le traitement du cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997021808A1 (fr) * 1995-12-08 1997-06-19 Hybridon, Inc. Oligonucleotides antisens modifies specifiques de vegf
WO1998037194A1 (fr) * 1997-02-19 1998-08-27 Human Genome Sciences, Inc. Membre d'une famille ell de facteurs d'allongement de polymerase ii d'arn appele ell2

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997021808A1 (fr) * 1995-12-08 1997-06-19 Hybridon, Inc. Oligonucleotides antisens modifies specifiques de vegf
WO1998037194A1 (fr) * 1997-02-19 1998-08-27 Human Genome Sciences, Inc. Membre d'une famille ell de facteurs d'allongement de polymerase ii d'arn appele ell2

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
PATTON W F ET AL: "COMPONENTS OF THE PROTEIN SYNTHESIS AND FOLDING MACHINERY ARE INDUCED IN VASCULAR SMOOTH MUSCLE CELLS BY HYPERTROPHIC AND HYPERPLASTIC AGENTS", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 270, no. 36, 8 September 1995 (1995-09-08), pages 21404 - 21410, XP002015479, ISSN: 0021-9258 *
ROMAGNOLO B ET AL: "Estradiol-dependent uterine leiomyomas in transgenic mice", JOURNAL OF CLINICAL INVESTIGATION, vol. 98, no. 3, 1 August 1996 (1996-08-01), pages 777 - 784-785, XP002096581, ISSN: 0021-9738 *
SHANAHAN, C. & WEISSBERG, P.: "Smooth muscle cell heterogeneity : patterns of gene expression in vascular smooth muscle cells in vitro and in vivo", ARTERIOSCLEROSIS, THROMBOSIS, AND VASCULAR BIOLOGY., vol. 18, March 1998 (1998-03-01), pages 333 - 338, XP000867761, ISSN: 1079-5642 *
WORIAX VELINDA L ET AL: "Mechanistic studies of the translational elongation cycle in mammalian mitochondria.", BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1352, no. 1, 1997, pages 91 - 101, XP000960429, ISSN: 0006-3002 *
XIN, H. ET AL.: "Cloning and expression of mitochondrial translation elongation factor Ts from bovine and human liver", JOURNAL OF BIOLOGICAL CHEMISTRY., vol. 270, 21 July 1995 (1995-07-21), pages 17243 - 17249, XP002129735, ISSN: 0021-9258 *
ZIBARA K. ET AL.: "Identification and cloning of a new gene (2A3-2), homologous to human translational elongation factor, upregulated in a proliferating rat smooth muscle cell line and in carotid hyperplasia.", ARTERIOSCLER THROMB VASC BIOL 1999 JUL;19(7):1650-7, XP000867756 *

Also Published As

Publication number Publication date
WO2000071708A2 (fr) 2000-11-30
FR2793798A1 (fr) 2000-11-24

Similar Documents

Publication Publication Date Title
MXPA02000992A (es) Microarreglos y su fabricacion.
NO20014058L (no) TRPM-2-antisense-terapi
WO2001000244A3 (fr) Techniques de traitement utilisant des conjugues maytansinoides-anticorps anti-erbb
AU2085201A (en) Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death
WO2000071703A3 (fr) Inhibition d'histone deacetylase
WO2002080754A3 (fr) Methodes d'utilisation d'une annexine permettant de visualiser la mort cellulaire in vivo et de traiter des etats pathologiques
CA2296769A1 (fr) Facteur modifie affectant le tissu dorsal et composition a base de ce facteur
WO2000029574A3 (fr) Genes associes a des inflammations
AP2004003026A0 (en) Methods for treating ocular neovascular diseases.
WO2000012726A3 (fr) Heparinases a conception rationnelle derivees de l'heparinase i et ii
ZA993777B (en) Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases.
WO2000061622A3 (fr) Genes associes aux maladies du rein
WO2000050588A3 (fr) Genes associes a des maladies du colon
MA27343A1 (fr) 1-amino triazolo [4,3-a] quinazoline-5-ones et/ou -5-thiones inhibitrices de phosphodiesterases iv.
MXPA00007634A (es) Nuevos compuestos de triazol (4,5-d) pirimidina.
WO1999025843A3 (fr) Kinase humaine de controle, hcds1, compositions et procedes
WO1999067384A3 (fr) Genes associes au cancer de la prostate
WO1995006764A3 (fr) Oligonucleotides ayant une activite de segmentation de l'arn
WO2002004677A3 (fr) Procede destine au diagnostic et au traitement de troubles mentaux
ZA200202939B (en) Coking reduction in cracking reactors.
AU6425800A (en) Agents for the diagnosis, prognosis and treatment of malignant diseases
WO2000071708A3 (fr) UTILISATION DE EF-Ts DANS LE CADRE DES HYPERPLASIES DES CELLULES MUSCULAIRES LISSES (CML)
WO2001041709A3 (fr) Methodes de traitement de maladie et d'inflammation liees a la mort de cellule
WO2000040722A3 (fr) Genes de synthese de l'insuline
ZA200104117B (en) The use of aryl-substituted cyclobutylalkylamines for treating urinary incontinence.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP